For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
The immuno-oncology revolution has delivered significant, durable responses for a sub-group of patients. However, these therapies are expensive and associated with side effects, while not ineffective for many. To fully unleash the power of immuno-oncology, new and improved biomarkers are needed that can accurately predict therapeutic responses for larger patient subsets.
To support you in your research to identify and validate immuno-oncology biomarkers, our comprehensive range of flexible and validated research solutions is on hand. Our immuno-oncology range includes products for key immunotherapy targets, including PD-L1, CTLA-4, LAG3 and TIM3.
Take a flexible approach
Our antibodies and assays to immuno-oncology targets are available in multiple formats: whether you are looking for a conjugated recombinant primary antibody, ELISA kit, or BSA-only formulation, search our catalog to find the right format for your research.
Generate data you can trust
To give you specific and reproducible results, our antibodies and assays are supported by extensive data and validation in healthy and diseased tissues and relevant applications. Our immuno-oncology range also includes knockout-validated antibodies for confirmed specificity and CRISPR-engineered knockout cell lines to validate your target or assay function.
Here we have highlighted some of our most popular immuno-oncology research antibodies to simplify your selection.
PD-L1 is one of the most well-known immuno-oncology biomarkers. Our knockout-validated PD-L1 [clone 28-8] rabbit recombinant monoclonal antibody is a leader in this space and allows you to investigate PD-L1 across multiple applications in a consistent manner. Showing no cross-reactivity to the highly homologous PD-L2, you can ensure you generate specific and sensitive data.
CTLA4 was the target of the first immune checkpoint inhibitor antibody for the treatment of cancer. Advance your own CTLA-4 research for the next immunotherapy breakthrough using our range of CTLA-4 reagents.
PD-1 has been targeted with key immuno-oncology drugs, such as ipilimumab and nivolumab. Study this important immune checkpoint protein with our conjugated and unconjugated recombinant primary antibodies.
Activate your immune response and your research with our conjugated and unconjugated antibodies to CXCR4.
Investigate TNF-alpha in your immuno-oncology research.
Investigate the role of TIM-3 in T-cell exhaustion and examine the potential of this new immuno-oncology target.
Confidently study the immune checkpoint protein LAG-3 with our recombinant antibodies available with a variety of conjugates or use our antibody panel which contains six recombinant monoclonal antibodies to human LAG-3.
Can't see what you need? Whatever immuno-oncology target you are investigating, find the products you need in our extensive catalog.
Alexa Fluor® is a registered trademark of Life Technologies. Alexa Fluor® dye conjugates contain(s) technology licensed to Abcam by Life Technologies.